vitamin-b-12 and Ischemic-Stroke

Ischemic stroke is the most prevalent form of stroke and has a high incidence in older adults, characterized by high morbidity, mortality, disability, and recurrence rate. Vitamin B

Topics: Aged; Humans; Ischemic Stroke; Stroke; Vitamin B 12; Vitamin B 12 Deficiency; Vitamins

Stroke is a leading cause of morbidity and mortality worldwide. It inflicts immeasurable suffering on patients and their loved ones and carries an immense social cost. Efforts to mitigate the impact of stroke have focused on identifying therapeutic targets for the prevention and treatment. The gut microbiome represents one such potential target given its multifaceted effects on conditions known to cause and worsen the severity of stroke. Vitamin B12 (VB12) serves as a cofactor for two enzymes, methylmalonyl-CoA synthase and methionine synthase, vital for methionine and nucleotide biosynthesis. VB12 deficiency results in a buildup of metabolic substrates, such as homocysteine, that alter immune homeostasis and contribute to atherosclerotic disorders, including ischemic stroke. In addition to its support of cellular function, VB12 serves as a metabolic cofactor for gut microbes. By shaping microbial communities, VB12 further impacts local and peripheral immunity. Growing evidence suggests that gut dysbiosis-related immune dysfunction induced by VB12 deficiency may potentially contributes to stroke pathogenesis, its severity, and patient outcomes. In this review, we discuss the complex interactions of VB12, gut microbes and the associated metabolites, and immune homeostasis throughout the natural history of ischemic stroke.

Topics: Animals; Biomarkers; Brain-Gut Axis; Disease Susceptibility; Dysbiosis; Gastrointestinal Microbiome; Homocysteine; Humans; Ischemic Stroke; Metabolic Networks and Pathways; Neuroinflammatory Diseases; Risk Factors; Translational Research, Biomedical; Vitamin B 12; Vitamin B 12 Deficiency

Type 2 diabetes mellitus (T2DM) is a known risk factor for cardiovascular disease and stroke. Metformin is an old, relatively safe, first line therapy for T2DM; however, it has been associated with stroke.. To study the effects of metformin use and vitamin B12 deficiency on stroke rate among patients with T2DM.. We conducted a prospective study of patients admitted with ischemic stroke within 12 months (starting March 2020). We studied the clinical impact of metformin on vitamin B12 deficiency and stroke evolution. Student's t-test and ANOVA were used to compare the groups of patients and to determine whether there was any direct or indirect effect of metformin use on vitamin B12 deficiency and stroke.. In total, 80 patients were admitted with ischemic stroke. Clinical status and biochemical data were collected and compared with healthy volunteers. There were 39 diabetic patients, 16 took metformin for at least 1 year. Among those who took metformin for at least 1 year, 9 had vitamin B12 level < 240 pg/ml (56.2%); 23 diabetic patients did not get metformin and only 4 had vitamin B12 level < 240 pg/ml (17.4%) (P = 0.014).. T2DM is a significant risk factor to the development of ischemic stroke. We found an association between metformin use and vitamin B12 deficiency and an association between vitamin B12 deficiency and stroke risk in patients with T2DM. Diabetic patients who are taking metformin should monitor their vitamin B12 level.

Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ischemic Stroke; Metformin; Prospective Studies; Stroke; Vitamin B 12; Vitamin B 12 Deficiency

Autonomic dysfunction is common in patients with ischemic stroke. An ischemic stroke may induce abnormalities in autonomic tone, resulting in poor heart rate regulation and an increased risk of severe cardiac arrest and sudden death. Heart rate variability (HRV) is a reliable index for evaluating autonomic dysfunction. Vitamin B12 deficiency is frequent among older adults and is a known risk factor for ischemic stroke. As vitamin B12 deficiency affects the peripheral nerves and the central nervous system, it can lead to autonomic dysfunction. However, no study has been published on the correlation between HRV and vitamin B12 status in patients with ischemic stroke. This study aimed to investigate the relationship between HRV and vitamin B12 status and to determine whether the serum vitamin B12 level can be a predictor of HRV parameters. This retrospective study enrolled patients with ischemic stroke between January 2015 and December 2022. The patients underwent serum vitamin B12 level measurements and 24-h Holter monitoring. Pearson correlation analysis was used to investigate the correlation between serum vitamin B12 levels and HRV parameters. The impact of serum vitamin B12 status on HRV parameters was determined using multiple linear regression analysis. A total of 87 patients with ischemic stroke were included in this study. HRV parameters were significantly correlated with serum vitamin B12 status in the frequency domain. In multiple linear regression analysis, the serum vitamin B12 status was a significant predictor of HRV parameters. HRV parameters may be correlated with serum vitamin B12 status in patients with ischemic stroke. Therefore, the serum vitamin B12 status may be a significant predictor of autonomic dysfunction. Our results may provide objective evidence for the impact of serum vitamin B12 status on autonomic dysfunction in patients with ischemic stroke.

Topics: Aged; Heart Rate; Humans; Ischemic Stroke; Primary Dysautonomias; Retrospective Studies; Stroke; Vitamin B 12; Vitamin B 12 Deficiency

Severely elevated serum homocysteine is a rare cause of ischaemic stroke and extra-cranial arterial and venous thrombosis. Several factors can lead to mild elevation of homocysteine including dietary folate and B12 deficiency, and genetic variants of the methylenetetrahydrofolate reductase (MTHFR) enzyme. The use of Anabolic androgenic steroid (AAS) is under-reported, but increasingly linked to ischaemic stroke and can raise homocysteine levels.. We present a case of a man in his 40s with a large left middle cerebral artery (MCA) territory ischaemic stroke and combined multifocal, extracranial venous, and arterial thrombosis. His past medical history was significant for Crohn's disease and covert use of AAS. A young stroke screen was negative except for a severely elevated total homocysteine concentration, folate and B12 deficiencies. Further tests revealed he was homozygous for the methylenetetrahydrofolate reductase enzyme thermolabile variant (MTHFR c.667 C > T). The etiology of this stroke was a hypercoagulable state induced by raised plasma homocysteine. Raised homocysteine in this case was likely multifactorial and related to chronic AAS use in combination with the homozygous MTHFR c.677 C > T thermolabile variant, folate deficiency and, vitamin B12 deficiency.. In summary, hyperhomocysteinemia is an important potential cause of ischaemic stroke and may result from genetic, dietary, and social factors. Anabolic androgenic steroid use is an important risk factor for clinicians to consider, particularly in cases of young stroke with elevated serum homocysteine. Testing for MFTHR variants in stroke patients with raised homocysteine may be useful to guide secondary stroke prevention through adequate vitamin supplementation. Further studies looking into primary and secondary stroke prevention in the high-risk MTHFR variant cohort are necessary.

Topics: Anabolic Androgenic Steroids; Brain Ischemia; Folic Acid; Genotype; Homocysteine; Humans; Hyperhomocysteinemia; Ischemic Stroke; Male; Methylenetetrahydrofolate Reductase (NADPH2); Risk Factors; Stroke; Thrombosis; Vitamin B 12

Stroke remains the second leading cause of death world wide after ischaemic heart disease. Stroke occurs mainly due to infarction which accpounts for 85% of etiological factors and 15% due to hemorrhage. Hyperhomocysteinemia is associated with premature atherosclerosis and vascular events and it is an important risk factor for cerebrovascular accidents.. Case will be selected from patients admitted to medical wards in Navodaya Medical College, Raichur. Duration based study with a minimum of 50 cases for a period of 18 months from august 2019. In all patients admitted with symptoms suggestive of stroke careful methodical examination of central nervous system carried out recording all physical signs in order. In all cases with the help of close relatives the preceding symptoms and risk factors were enquired all patients were subjected to CT scan brain, CBC, FBS, PPBS, lipid profile and serum homocysteine levels were done.. In our study we observed that the serum homocysteine levels were elevated in ischemic stroke significantly. The mean serum homocysteine levels were higher in non diabetics(29.57 micromole/ litre) than diabetics (20.75 micromole/litre) and difference was statistically significant (P<0.001). Mean serum Homocysteine levels were higher in age group <65 years(28.73 micromole/litre) than patient age >65 years (20.50 micromole/litre) and the difference was statistically significant (p<0.001). Mean serum heomocysteine levels were higher in hypertensives (26.73 micromole/litre) than normotensive (23.28 micromole/litre) however the difference was statistically not significant (p>0.001).The mean serum homocysteine levels were higher in patients with normal lipid profile(30.97 micromole/litre) than patients with dyslipidemia (21.92 micromole/litre) and the difference was statistically significant (p<0.001).. The present study revealed that hyperhomocysteinemia appears to be an important risk factor for ischemic stroke. It is therefore important to use serum homocysteine as an important tool to investigate all cases of ischemic stroke and if serum homocysteine is elevated patient should be put on multivitamins containing vitamin B12, folic acid and pyridoxine to reduce serum homocysteine levels.

Topics: Aged; Homocysteine; Humans; Hyperhomocysteinemia; Ischemia; Ischemic Stroke; Lipids; Risk Factors; Stroke; Vitamin B 12

A vitamin B12 deficiency (vit. B12 def.) is common in the elderly, because of changes in metabolism. Clinical studies have reported that a vit. B12 def. results in worse outcome after stroke, and the mechanisms through which a vit. B12 def. changes the brain requires further investigation. This study investigated the role of vit. B12 def. on stroke outcome and mechanisms using aged female mice. Eighteen-month-old females were put on a control or vit. B12 def. diet for 4 weeks, after which an ischemic stroke was induced in the sensorimotor cortex. After damage, motor function was measured, the animals were euthanized, and tissues were collected for analysis. Vit. B12 def. animals had increased levels of total homocysteine in plasma and liver, and choline levels were also increased in the liver. Vit. B12 def. animals had larger damage volume in brain tissue and more apoptosis. The cecum tissue pathway analysis showed dysfunction in B12 transport. The analysis of mitochondrial metabolomics in brain tissue showed reduced levels of metabolites involved in the TCA cycle in vit. B12 def. animals. Motor function after stroke was impaired in vit. B12 def. animals. A dietary vit. B12 def. impairs motor function through increased apoptosis and changes in mitochondrial metabolism in brain tissue.

Topics: Animals; Brain; Cecum; Diet; Female; Folic Acid; Homocysteine; Ischemic Stroke; Mice; Stroke; Vitamin B 12; Vitamin B 12 Deficiency

Topics: Brain Ischemia; Folic Acid; Homocysteine; Humans; Ischemic Stroke; Stroke; Vitamin B 12